Guidance Documents
2 Results
Guidance Documents
Use of Existing DEA-Form 222s (U.S. Official Order Forms – Schedules I & II) after Removal of X-Waiver
This guidance document provides information regarding a practitioner’s use of existing Drug Enforcement Administration (DEA)-Form 222s after Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act (CAA) of 2023.
ID:
DEA-DC-069
Component
Diversion Control Program (DEA)
Date Issued: April 4, 2023
Guidance Documents
Elimination of Patient Limits for Prescribing Buprenorphine for Treatment of Opioid Use Disorder (OUD) under the Consolidated Appropriations Act (CAA) of 2023
This guidance document provides information regarding the elimination of limitations on the number of patients with OUD that a practitioner may treat with buprenorphine, as a result of Congress’s enactment of the CAA.
ID:
DEA-DC-066
Component
Diversion Control Program (DEA)
Date Issued: March 21, 2023